Single-chain antibodies to block HIV transcription and prevent reactivation from latently infected resting CD4+ T cells
单链抗体可阻断 HIV 转录并防止潜伏感染的静息 CD4 T 细胞重新激活
基本信息
- 批准号:10308728
- 负责人:
- 金额:$ 20.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-12-01 至 2022-06-30
- 项目状态:已结题
- 来源:
- 关键词:AdoptedAffinityAftercareAnimalsAntibodiesAreaBindingBiogenesisBiological AssayBlocking AntibodiesCD4 Positive T LymphocytesCell NucleusCell divisionCellsClinicalDataDevelopmentDisease remissionDissociationEffector CellEpitopesGenetic TranscriptionGenomeGoalsGrantHIVHeat-Shock Proteins 90Heat-Shock ResponseHumanImmuneImmunizationIn VitroInfection preventionIntegration Host FactorsLengthLongevityMediatingModelingMolecular ConformationMusNuclear EnvelopeNuclear ExportNucleic AcidsOralPatientsPharmaceutical PreparationsPhenotypePhysiologicalPlasmaProcessProtein Export PathwayProteinsProvirusesRNARNA SplicingRNA chemical synthesisRecruitment ActivityReporterReporter GenesReportingResearchResistanceRestRoleSamplingSpecificitySpleenSurfaceSystemTherapeuticTissuesTranscriptViral GenomeViremiaVirusWithholding Treatmentantibody librariesantiretroviral therapybaseclinically relevantcytotoxicitydesignhumanized mousein vitro Modelinhibitorinnovationnext generationnovelnovel therapeuticspreventpromoterprospectivereactivation from latencyresponserev-Responsive Elementsside effectstemtherapeutic candidatetranscription factortranslation factorviral RNAviral genomicsvirtual
项目摘要
PROJECT SUMMARY
Despite decades of successful antiretroviral therapy (ART), persistent HIV-infected resting CD4+ T cells can
remain undetected in tissue reservoirs. HIV replication is cytopathic in activated CD4+ T cells; however, a fraction
of HIV-infected activated CD4+ T cells revert to the resting G0 phenotype in tissue reservoirs. These persistent
HIV-infected resting CD4+ T cells undergo intermittent activation and produce fully infectious virus. HIV is
invariably detected in the plasma when patients discontinue ART because plasma viremia is reseeded by
intermittent activation of persistent HIV-infected resting CD4+ T cells in the tissue reservoirs.
In response to RFA-AI-19-072: Novel Therapeutics Directed to Intracellular HIV Targets, we propose an
innovative analytic bioassay to identify next-generation single-chain antibodies that sustain HIV remission. Our
research is focused on the essential role of heat shock protein 90 (Hsp90) in HIV replication, and we have shown
that mild heat shock (39.5°C) accelerates HIV transcription. Increased Hsp90 activity at 39.5°C was critical for
full-length HIV RNA synthesis by host transcription factors, and we have shown that 39.5°C reactivates latent
HIV replication in ART-suppressed aviremic HIV-infected patient samples, in human resting CD4+ T cells isolated
from fully suppressed humanized mice, and in three distinct in vitro models of HIV latency.
Reactivation of latent HIV depends on multiple host proteins interacting with their HIV counterpart, and the
recently developed QUECEL (quiescent effector cell latency) model of HIV latency is an ideal in vitro system to
identify single-chain antibodies that disrupt HIV-host protein interactions. The QUECEL carries a modified HIV
provirus that depends on all the HIV-host protein interactions to reactivate latent HIV RNA synthesis. The latent
QUECEL depends on host protein interaction for both the HIV Tat-mediated transcription and HIV Rev-mediated
export of the full-length viral genome, and we anticipate that single-chain antibodies will disrupt these critical
HIV-host protein interactions required for reactivation of HIV latency. We have proof that the QUECEL can be
reactivated at 39.5°C and designed a high-complexity single-chain antibody library to selectively enrich for
candidates that prevent QUECEL reactivation. The prospective antiviral candidates will then be further enriched
in resting CD4+ T cells isolated from ART-treated aviremic patients, and we anticipate identifying potent single-
chain antibodies that disrupt the HIV-host protein interactions required to reactivate HIV from latency.
Our analytic bioassay is innovative because 1) mild heat shock activation is physiologically similar to the
intermittent cellular activation occurring in persistent HIV-infected tissue reservoirs and 2) the small size of single-
chain antibodies will increase the target range to the surface area of HIV proteins, effectively blocking critical
host-protein interactions. We propose to use mild heat shock to identify potent antiviral single-chain antibodies
in the following Specific Aims: 1) Selectively enrich for single-chain antibodies that prevent reactivation of latent
QUECEL, and 2) Identify potent single-chain antibodies that block HIV transcription.
项目总结
尽管几十年的抗逆转录病毒治疗(ART)取得了成功,但持续感染艾滋病毒的静息CD4+T细胞可以
在组织储藏室中仍未被检测到。HIV复制是激活的CD4+T细胞的细胞病变;然而,一小部分
在组织储存库中,HIV感染的活化的CD4+T细胞恢复到静止的G0表型。这些坚持不懈
HIV感染的静止的CD4+T细胞经历间歇性激活,并产生完全具有感染性的病毒。艾滋病毒是
当患者停止抗逆转录病毒治疗时,总是在血浆中检测到,因为血浆病毒血症是通过
组织储存库中持续感染艾滋病毒的静息CD4+T细胞的间歇性激活。
为了回应RFA-AI-19-072:针对细胞内HIV靶点的新型治疗药物,我们提出了一种
创新的分析生物测定,以确定维持艾滋病毒缓解的下一代单链抗体。我们的
研究的重点是热休克蛋白90(Hsp90)在HIV复制中的重要作用,我们已经证明
温和的热休克(39.5摄氏度)加速了艾滋病毒的转录。在39.5摄氏度时增加Hsp90活性对
宿主转录因子合成全长HIV RNA,我们发现39.5℃重新激活潜伏
ART抑制的无核型HIV感染者样本中HIV的复制,分离的人类静息CD4+T细胞
来自完全受抑制的人源化小鼠,并在三个不同的体外模型中潜伏着艾滋病毒。
潜伏的HIV的重新激活依赖于多个宿主蛋白与其对应的HIV蛋白相互作用,而
最近开发的HIV潜伏期的QUECEL(静态效应细胞潜伏期)模型是一种理想的体外系统
识别破坏HIV-宿主蛋白相互作用的单链抗体。QUECEL携带一种改良的艾滋病毒
前病毒依赖于所有HIV-宿主蛋白的相互作用来重新激活潜在的HIV RNA合成。潜伏者
QUECEL依赖于HIV Tat介导的转录和HIV Rev介导的宿主蛋白相互作用
输出全长病毒基因组,我们预计单链抗体将破坏这些关键的
HIV-宿主蛋白相互作用是重新激活HIV潜伏期所必需的。我们有证据证明QUECEL可以
在39.5℃下重新激活,并设计了一个高复杂性的单链抗体库,用于选择性地富集
阻止QUECEL重新激活的候选人。然后,未来的抗病毒候选药物将进一步丰富
在静息状态下,从接受抗逆转录病毒治疗的无氧血症患者中分离出CD4+T细胞,我们预计将鉴定出有效的单一...
破坏HIV-宿主蛋白相互作用的链抗体,这些相互作用是从潜伏期重新激活HIV所需的。
我们的分析生物测定是创新的,因为1)温和的热休克激活在生理上类似于
在持续感染HIV的组织储存库中发生间歇性细胞激活,以及2)单个小尺寸的
链抗体会将靶向范围扩大到HIV蛋白的表面积,有效地阻断关键的
宿主与蛋白质的相互作用。我们建议使用轻度热休克来鉴定有效的抗病毒单链抗体。
在以下特定目的中:1)选择性地富含单链抗体,以防止潜伏期重新激活
QUECEL,以及2)识别阻止HIV转录的有效单链抗体。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Cheryl Stoddart其他文献
Cheryl Stoddart的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Cheryl Stoddart', 18)}}的其他基金
Inhibition of heat shock protein 90 for sustained remission of HIV from persistent tissue reservoirs
抑制热休克蛋白 90 使持久性组织储存库中的 HIV 持续缓解
- 批准号:
10184988 - 财政年份:2020
- 资助金额:
$ 20.19万 - 项目类别:
HUMANIZED MOUSE MODELS FOR HIV THERAPEUTICS DEVELOPMENT
用于艾滋病毒治疗开发的人源化小鼠模型
- 批准号:
9915757 - 财政年份:2019
- 资助金额:
$ 20.19万 - 项目类别:
IGF::OT::IGF "HUMANIZED MOUSE MODELS FOR HIV THERAPEUTICS DEVELOPMENT"
IGF::OT::IGF“用于艾滋病治疗开发的人性化小鼠模型”
- 批准号:
8936706 - 财政年份:2013
- 资助金额:
$ 20.19万 - 项目类别:
IGF::OT::IGF "HUMANIZED MOUSE MODELS FOR HIV THERAPEUTICS DEVELOPMENT"
IGF::OT::IGF“用于艾滋病治疗开发的人性化小鼠模型”
- 批准号:
9004371 - 财政年份:2013
- 资助金额:
$ 20.19万 - 项目类别:
Tissue Based Small Animal Model for HIV Drug Discovery
用于 HIV 药物发现的基于组织的小动物模型
- 批准号:
7789059 - 财政年份:2006
- 资助金额:
$ 20.19万 - 项目类别:
TISSUE BASED SMALL ANIMAL MODEL FOR HIV DRUG DISCOVERY
用于艾滋病毒药物发现的基于组织的小动物模型
- 批准号:
7543538 - 财政年份:2006
- 资助金额:
$ 20.19万 - 项目类别:
TISSUE-BASED SMALL ANIMAL MODEL FOR HIV DRUG DISCOVERY
用于艾滋病毒药物发现的基于组织的小动物模型
- 批准号:
6348654 - 财政年份:2000
- 资助金额:
$ 20.19万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
Continuing Grant














{{item.name}}会员




